Cargando…

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

Prostate cancer is one of the most common malignant tumors in men. Initially, it is androgen-dependent, but it eventually develops into castration-resistant prostate cancer (CRPC), which is incurable with current androgen receptor signaling target therapy and chemotherapy. Immunotherapy, specificall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Pengfei, Wasielewski, Logan J., Yang, Joy C., Cai, Demin, Evans, Christopher P., Murphy, William J., Liu, Chengfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394279/ https://www.ncbi.nlm.nih.gov/pubmed/35892678 http://dx.doi.org/10.3390/biomedicines10081778

Ejemplares similares

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
por: Xu, Pengfei, et al.
Publicado: (2023)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
por: Zhang, Jinpeng, et al.
Publicado: (2022)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy
por: Cucchiara, Vito, et al.
Publicado: (2017)

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy
por: Olejarz, Wioletta, et al.
Publicado: (2020)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies
por: Zahavi, David, et al.
Publicado: (2023)

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
por: Giles, Amber J., et al.
Publicado: (2018)

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment
por: Jiang, Zhou, et al.
Publicado: (2020)

Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
por: Miyazaki, Tsubasa, et al.
Publicado: (2020)

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling
por: Liu, Chengfei, et al.
Publicado: (2021)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
por: Barnestein, Robby, et al.
Publicado: (2022)

The Effects of Long-Term Immunosuppressive Therapies on the Structure of the Rat Prostate
por: Grabowska, Marta, et al.
Publicado: (2020)

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
por: Wang, Junjian, et al.
Publicado: (2016)

Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein–Barr Virus-Associated Malignancies
por: Zheng, Xueyi, et al.
Publicado: (2022)

Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
por: Setlai, Botle Precious, et al.
Publicado: (2022)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
por: Otegui, Nerea, et al.
Publicado: (2023)

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
por: Vanderstraeten, Anke, et al.
Publicado: (2014)

Targeting immunosuppression by TGF-β1 for cancer immunotherapy
por: de Streel, Grégoire, et al.
Publicado: (2021)

Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022)

Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma
por: Xia, Yidan, et al.
Publicado: (2022)

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
por: Xu, Yanyan, et al.
Publicado: (2022)

Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer
por: Cappellesso, Federica, et al.
Publicado: (2022)

Immunotherapy and gene therapy in prostate cancer treatment
por: Grozescu, T, et al.
Publicado: (2017)

Effects of an immunosuppressive treatment on the rat prostate
por: Grabowska, Marta, et al.
Publicado: (2016)

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer()
por: Lombard, Alan P, et al.
Publicado: (2019)

Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes
por: Ning, Shu, et al.
Publicado: (2022)

Apoptosis-Related Gene-Mediated Cell Death Pattern Induces Immunosuppression and Immunotherapy Resistance in Gastric Cancer
por: Yuan, Xiaolu, et al.
Publicado: (2022)

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
por: Yang, Minglei, et al.
Publicado: (2022)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021)

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2018)

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad
por: Bleve, Augusto, et al.
Publicado: (2020)

2025 Targeting immunosuppressive myeloid cells to enhance cancer immunotherapy
por: Lu, Xin
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fa4hl54mvd7rgf56iof97r73tc